前列腺动脉栓塞作为前列腺癌根治性放疗前辅助治疗的概念验证研究
该概念验证研究纳入9例接受前列腺动脉栓塞(PAE)的前列腺癌合并良性前列腺增生患者,其中5例在本机构完成放疗及随访。仅前列腺放疗的两例患者膀胱、直肠和阴茎球平均剂量分别降低23.2%、39.8%和22.9%,而盆腔淋巴结覆盖者剂量学无明显差异。
要点
- PAE可显著缓解下尿路症状并缩小前列腺体积,为放疗前辅助治疗提供概念验证。
- PAE后行前列腺放疗可降低膀胱、直肠和阴茎球平均剂量,可能减少放疗相关毒性。
- 需淋巴结覆盖者PAE后剂量学无明显获益,提示获益人群可能限于前列腺局部放疗者。
核心结论
- PAE是前列腺癌放疗前缓解下尿路症状并实现前列腺体积缩小的有临床意义的辅助治疗,可降低放疗相关毒性。
研究设计与样本
- 中位随访自PAE起为18个月,放疗期间不良事件采用常见不良事件评价标准(CTCAE)评分系统量化。
- 对5例患者比较PAE前后计划,将PAE后计划行等体积扩张至PAE后实测体积缩小程度后比较危及器官平均剂量。
主要发现
- PAE后前列腺体积平均缩小23.1%(范围7.2%-47.7%)。
- 放疗期间无CTCAE 3级(严重)或以上不良事件。
- 仅前列腺放疗的PT-01和PT-02,PAE后计划较PAE前计划膀胱、直肠和阴茎球平均剂量分别平均降低23.2%、39.8%和22.9%。
- 接受淋巴结覆盖放疗的PT-03、PT-04和PT-05剂量学无显著差异,所有患者均无生化失败。
关键数值与推荐
- PAE后前列腺体积平均缩小23.1%(7.2%-47.7%)。
- 仅前列腺放疗者PAE后膀胱、直肠和阴茎球平均剂量分别平均降低23.2%、39.8%和22.9%。
临床怎么用
- 对合并良性前列腺增生下尿路症状的前列腺癌患者,可考虑在根治性放疗前行PAE以缓解症状并缩小前列腺体积。
- PAE后放疗可能降低前列腺局部放疗时膀胱、直肠和阴茎球剂量,但需淋巴结覆盖者剂量学获益不明显。
局限性
- 本研究为概念验证研究,样本量小(仅5例纳入分析),随访时间短(中位18个月)。
- PAE前计划与PAE后计划的剂量学比较采用等体积扩张方法,非直接比较实际治疗计划。
- 接受淋巴结覆盖放疗的病例数少(3例),剂量学差异需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostatic artery embolization (PAE) is an effective therapy for alleviating lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia; however, is not well studied in patients with concurrent prostate cancer (PCa). We demonstrate a proof of concept for PAE before definitive radiation therapy (RT) in patients with PCa. METHODS AND MATERIALS: From December 2017 to July 2019, 9 patients with PCa underwent PAE for the indication of LUTS from benign prostatic hyperplasia with concurrent PCa. Five received radiation and all follow-ups at our institution and were therefore included in the analysis. Median follow-up was 18 months from the time of PAE. Side effects during radiation were quantified using the Common Terminology Criteria for Adverse Events scoring system. Pre- and post-PAE plans were compared in the 5 patients by performing an isovolumetric expansion of the post-PAE plan (treated plan) equivalent to the measured volume reduction after PAE. Patient 1 (PT-01) and PT-02 had prostate RT alone whereas PT-03, PT-04, and PT-05 had prostate with elective nodal coverage RT. Mean doses to organs at risk were compared between the 2 plans. RESULTS: The mean International Prostate Symptom Score reduction after PAE was 13.8 (5.0-30.0; P = .02). The mean prostatic volume reduction after PAE was 23.1% (7.2%-47.7%). There were no Common Terminology Criteria for Adverse Events grade 3 (severe) or higher during radiation. Post-PAE plans in PT-01 and PT-02 had on average 23.2%, 39.8%, and 22.9% decrease in mean dose across the bladder, rectum, and penile bulb, respectively, compared with the pre-PAE plans. There were no appreciable differences in dosimetry in PT03, PT-04, and PT-05 who had nodal coverage. There was no biochemical failure in any of the patients. CONCLUSIONS: We demonstrate a proof of concept that PAE is a clinically significant adjunctive therapy for alleviating LUTS and achieving significant volume reduction before RT, resulting in decreased radiation-related toxicity from RT for PCa.
引用
- Peacock J, Sikaria D, Maun-Garcia L, et al. A Proof-of-Concept Study on the Use of Prostate Artery Embolization Before Definitive Radiation Therapy in Prostate Cancer. Adv Radiat Oncol. 2020. PMID: 33748542. doi:10.1016/j.adro.2020.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。